Shares of Zentalis Pharmaceuticals Inc. (ZNTL) are down more than 60% from their 52-week high of $31.46, recorded last May, and trade around $12.
The lead drug candidate is Azenosertib, a WEE1 inhibitor, in development for the treatment of cancer. Inhibition of WEE1, a DNA damage response kinase, drives cancer cells into mitosis without being able to repair damaged DNA, resulting in cell death. Currently, there are no FDA-approved WEE1 inhibitors. The company is also developing ZN-d5, a potent BCL-2 Inhibitor, as monotherapy and in combination with Azenosertib for the treatment of acute myeloid leukemia.
For comments and feedback contact: editorial@rttnews.com
May 22, 2026 14:46 ET Minutes of the latest Fed policy session was the highlight of the week along with survey data on the U.S. housing market. In Europe, survey data signaled the trends in the euro area private sector. Further, consumer price inflation data from the U.K. was in focus. In Asia, various economic indicators from China drew attention to the health of the economy.